Welcome to our dedicated page for Sotera Health news (Ticker: SHC), a resource for investors and traders seeking the latest updates and insights on Sotera Health stock.
Sotera Health Company provides sterilization solutions, lab testing and advisory services for the healthcare industry through Sterigenics, Nordion and Nelson Labs. News about SHC commonly covers quarterly and annual operating results, constant-currency revenue trends, Adjusted EBITDA commentary and outlook updates across those businesses.
Recurring company developments also include segment performance in outsourced terminal sterilization, irradiation services and laboratory testing, as well as governance changes, board committee assignments and capital-structure activity involving its Nasdaq-listed common stock. Sterigenics uses gamma irradiation, EO processing and E-beam irradiation for medical device, pharmaceutical, food safety and other application markets.
Sotera Health (Nasdaq: SHC) reported Q2 2026 net revenues of $321.4 million, up 9.2% year over year, or 8.0% on a constant currency basis. Net income rose to $53.6 million, or $0.19 per diluted share, versus $8.0 million or $0.03 in Q2 2025.
Adjusted EBITDA increased 10.0% with margin expanding to 51.6%, and Adjusted EPS grew 30% to $0.26. All three segments posted constant-currency revenue growth, led by Nordion at 16.7%. The company generated $88 million of Q2 operating cash flow and ended June 30, 2026 with a Net Leverage Ratio of 3.0x and about $950 million of available liquidity.
Sotera Health raised its full-year 2026 outlook, guiding net revenues to $1.236–$1.254 billion and Adjusted EBITDA to $634–$643 million, with expected constant-currency growth of 5.25–6.75% and 5.75–7.25%, respectively. Full-year Adjusted EPS is now projected at $0.95–$1.01.
Sotera Health (Nasdaq: SHC) plans to release its financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 6, 2026. Management will host a conference call at 9:00 a.m. EDT, with a live webcast and replay available via the company’s Investor Relations website.
Sotera Health (Nasdaq: SHC) announced a secondary offering of 31,838,253 common shares. All shares are being sold by affiliates of Warburg Pincus and GTCR; no other entities or individuals are selling. The Company is not issuing shares, receives no proceeds, but will pay offering expenses.
Sotera Health (Nasdaq: SHC) reported Q1 2026 net revenues up 10.0% (6.5% constant currency) and net income of $27 million ($0.09 diluted). Adjusted EBITDA rose 10.5% (6.9% constant currency); Adjusted EPS was $0.18 (+29%). Company reaffirmed 2026 outlook: net revenues +5.0%–6.5% and Adjusted EBITDA +5.5%–7.0% (constant currency).
Q1 highlights: Sterigenics revenue $186M, Nordion $42M, Nelson Labs $52M; net cash from operations $29M; net leverage 3.2x; >$900M available liquidity.
Sotera Health (Nasdaq: SHC) announced a planned leadership transition: Alton Shader will become CEO and join the Board effective May 26, 2026, succeeding Michael B. Petras, Jr., who will become Executive Chairman and remain actively involved as a full-time employee.
The release notes Sotera’s revenue growth from $630 million in 2016 to $1.164 billion in 2025 and an Adjusted EBITDA increase of more than $300 million since 2016. The company will host an earnings webcast on May 5, 2026 at 9:00 a.m. ET.
Sotera Health (Nasdaq: SHC) will release first-quarter 2026 results for the period ended March 31, 2026 before market open on Tuesday, May 5, 2026. Management will hold a conference call at 9:00 a.m. Eastern Daylight Time the same day to discuss operating and financial results.
A live webcast and accompanying materials will be available via the Investor Relations section of the company website, with a replay posted later on May 5. Updates on recent investor matters and Ethylene Oxide developments are published on the Investor Relations site.
Sotera Health (Nasdaq: SHC) appointed Kenneth D. Krause to its Board of Directors, effective March 16, 2026, and he will join the Audit Committee and the Litigation Committee. Krause brings public-company CFO experience from Rollins and MSA Safety and expertise in corporate strategy, capital allocation and governance. Constantine S. Mihas resigned from the Board effective March 16, 2026, due to a reduction in stockholder-designated director slots.
Sotera Health (Nasdaq: SHC) announced a secondary offering of 25 million common shares on March 4, 2026. All shares are being sold by affiliates of Warburg Pincus and GTCR; the company is not selling shares and will not receive proceeds.
Wells Fargo Securities is the underwriter; the company will pay offering expenses under its registration rights agreement. The offering will be made only by prospectus and a registration statement filed February 27, 2024, became effective automatically.
Sotera Health (Nasdaq: SHC) reported 2025 net revenues of $1.164B, up 5.7% (5.2% constant currency); net income of $78M ($0.27/diluted); Adjusted EBITDA of $594M (+8.2%); and Adjusted EPS of $0.86. This marks the 20th consecutive year of revenue growth. Balance sheet: $2.2B total debt, $345M cash, Net Leverage Ratio improved to 3.2x. 2026 outlook: net revenues $1.233–1.251B, Adjusted EBITDA $632–641M, Adjusted EPS $0.93–1.01, and capex $175–225M.
Sotera Health (Nasdaq: SHC) will release fourth-quarter and full-year 2025 financial results before market open on Tuesday, February 24, 2026. Management will host a conference call at 9:00 a.m. Eastern Time the same day and provide a live webcast and replay via the company Investor Relations site.
Presentation materials and periodic updates, including information related to Ethylene Oxide, will be posted on the Sotera Health Investor Relations web pages.